• Anne-Louise Arnett appointed CEO to accelerate BCAL's commercial roadmap
• Ms Arnett has over 25 years of experience in medical technology and successful product launches
• Shane Ryan appointed Director Clinical Affairs Breast Cancer to ensure continuity

BCAL Diagnostics Limited (ASX: BDX), an Australian healthcare company pioneering diagnostics for early detection of cancer, has appointed Anne-Louise (Annie) Arnett as Chief Executive Officer, effective 1 June 2026 to accelerate BCAL's commercial roadmap. Ms Arnett brings more than 25 years of senior commercial and operational leadership across the medical technology sector, with depth in diagnostics, capital equipment and regulated product portfolios. She has successfully launched diagnostic and medical technology products into Australian and international markets. Her appointment comes at a pivotal moment for BCAL, as the Company prepares to bring multiple new products to market and extend its reach beyond Australia. BCAL Executive Chair Jayne Shaw said, 'Annie is the right CEO to take BCAL into its next chapter. We have built a genuinely differentiated portfolio of early cancer detection products and the opportunity in front of us, both here in Australia and internationally is substantial. Annie has spent her career doing exactly what we need: taking innovative medical technology to market, building the commercial infrastructure to support it, and scaling organisations to meet that growth. Her deep familiarity with diagnostic and medical technology products, regulatory environments and international market entry will be invaluable as we execute our pipeline.' BCAL CEO Anne-Louise Arnett said: 'I am excited to be joining BCAL and working with the Board and team on the compelling product pipeline, from BREASTESTplus through to the Multi Cancer Early Detection (MCED) platform. Early cancer detection is one of the most important areas in healthcare, and BCAL has built something genuinely special and meaningful to patients. I look forward to bringing my commercial and organisational experience to the opportunities, both domestically and across international markets to realise the potential this technology can bring for BCAL and its shareholders.' Shane Ryan, outgoing CEO, will continue with BCAL Diagnostics in the role of Director Clinical Affairs Breast Cancer, ensuring full continuity of BCAL's core product program during the leadership transition. Jayne Shaw, who has served as Executive Chair since the Company's ASX listing, will transition to Non-Executive Chair effective 1 July 2026, reflecting the natural evolution of BCAL's governance structure as the Company matures.

BCAL is preparing to bring multiple new products to market and extend its reach beyond Australia under the leadership of new CEO Anne-Louise Arnett, who has over 25 years of experience in the medical technology sector.